Pricing of ADC Drugs

​In the US market, the most expensive priced ADC drug is Pfizer's Bebosan (ocetuzumab), with an annual treatment cost of $290,000 for a 60kg patient, equivalent to nearly 2 million Chinese yuan (CNY 1.95 million). The next highest priced ADC is GSK's Blenrep, priced at 1.36 million yuan. These two are the only ADC drugs priced over one million yuan.

2023-06-05Learn more

Information on some ADC listed drugs

Who is KADCYLA for? Early Breast Cancer KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA

2023-04-21Learn more

Jiangsu Public TV visit MediLink

2022-10-28Learn more

FDA Clearance of IND Application for YL202

September 3, 2022 - MediLink Therapetutics announced that YL202 has been cleared for its IND application by the U.S. Food and Drug Administration for Phase I first-in-human study

2022-09-03Learn more

1st patient dosed with product YL201 in the United States

2022-04-23Learn more

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of MediLink's new generation Antibody-Drug Conjugate (ADC) pipeline, as well as early discovery and development of novel conjugated drugs.

2022-04-14Learn more

FDA Clearance of IND Application for YL201

2022-04-12Learn more

MediLink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou MediLink Therapeutics Ltd. (MediLink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a $50 million series A financing, to accelerate its innovative pipeline development and to support its unique conjugate technology platform. The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.

2021-03-01Learn more